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Background
Haemolysis occurs in a number of haematologic and
non-haematologic diseases, including sickle cell disease,
malaria and sepsis. Elevated extracellular haemoglobin
(Hb) can trigger specific events that are associated with
adverse clinical outcomes. For example, in sickle cell dis-
ease, cell-free haemoglobin has been proposed to reduce
nitric oxide (NO) bioavailability and induce vascular oxi-
dative stress and, possibly, inflammation [1]. Hydro-
xyurea, a drug used commonly as a therapy for sickle cell
disease, may exert some of its effects by acting as a NO
donor, in vivo [2]. This study aimed to compare the
effects of haemolytic and inflammatory stimuli on blood
vessel leukocyte recruitment in vivo. The effects of the
acute administration of hydroxyurea (HU) or an NO
donor on these alterations were also investigated.
Methods
Inflammatory or hemolytic processes were induced in
C57BL/6 mice (2-4 months old) and cremaster muscles
of mice were prepared for intravital microscopy (IVM),
according to protocols described in figure 1. Plasma-free
Hb was measured with Drabkin’s solution.
Results
C57BL/6 mice that received water i.v. (H2O mice) pre-
sented marked vascular haemolysis after 15 min; levels of
plasma Hb were more than doubled in H2O mice, com-
pared to mice that receiving PBS i.v. (2.57±0.43g/dL, 1.08
±0.08g/dL Hb, respectively, p<0.01, n=3-5), and resembled
those of SCD mice (data not shown). In contrast, C57BL/6
mice (n=3) that received an inflammatory stimulus (TNF-
a) showed no alteration in plasma free Hb levels (1.29
±0.43 g/dL, 1.23±0.09 g/dL; PBS and TNF-a, respectively).
IVM demonstrated that both the inflammatory and hae-
molytic stimuli induced leukocyte adhesion to vessel walls
(3.57±0.84; 11.07±0.92; 7.25±1.20 [100µm-1] for PBS,
TNF-a and H2O, respectively, p<0.05, N=15-30 venules),
as well as leukocyte extravasation (1.07±0.17; 4.02±0.39;
2.97±0.49 [per 100 µm x 50 µm] for PBS, TNF-a and
H2O, respectively, p<0.05, N=15-30 venules). Surprisingly,
when HU was given simultaneously with TNF-a or follow-
ing H2O, this drug was able to prevent leukocyte recruit-
ment in both models, reducing both leukocyte adhesion
(7.40±0.47; 2.79±0.34 [100 µm-1] for TNF-a+PBS and
TNF-a+HU, respectively, p<0.0001, n=30-60 venules; and
7.84±0.73; 2.41±0.37 for H2O+PBS and H2O+HU,
p<0.0001, n=20-30 venules) and leukocyte extravasation
(3.88±0.26; 1.22±0.18 for TNF-a+PBS and TNF-a+HU,
p<0.0001, n=30-60 venules and 2.98±0.32; 1.94±0.21 for
H2O+PBS and H2O+HU, p<0.0001, n=20-30 venules) and
increased leukocyte rolling (18.11±1.58; 25.48±5.01 for
TNF-a+PBS and TNF-a+HU, respectively, p<0.05,
n=30-60 venules and 11.56±1.47; 32.47±3.54 for H2O+PBS
and H2O+HU, p<0.0001, n=20-30 venules). Additionally,
DEANO was also able to reverse the inflammatory process
installed by TNF-a, reducing leukocyte adhesion (10.24
±1.49; 11.45±1.40 for TNF-a before and after vehicle con-
trol, n=21-22 venules; 7.63±0.63; 3.76±0.41 for TNF-a,
before and after DEANO, p<0.01; n=29-35 venules) and
extravasation (1.95±0.29; 3.23±0.44 before and after vehicle
control, p<0.05, n=21-22 venules; 2.49±0.25; 2.24±0.24
before and after DEANO, n=29-35 venules).
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Conclusion
The induction of intravascular haemolysis in mice may
rapidly induce alterations in leukocyte recruitment in
vessels, similar to those observed following a substantial
inflammatory stimulus. Acute administration of HU was
found to reverse the effects of both inflammatory and
haemolytic stimuli, in a manner similar to an established
NO donor (DEANO). Results indicate that HU appears
to have immediate beneficial effects in blood vessels.
Data support growing evidence suggesting that one of
the principal mechanisms by which HU exerts its effects
in vivo is by a nitric oxide donor/cGMP-stimulating
effect; moreover, targeting the NO/cGMP may be an
important approach for therapies for haemolytic, as well
as for inflammatory, diseases. Further experiments are
underway to confirm that HU acts via NO/cGMP in the
haemolytic model.
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Figure 1 Protocols used in IVM.
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